• Reducing
neurologic disability or relapses in patients with secondary
progressive, progressive relapsing, or worsening relapsing-remitting
multiple sclerosis (MS)
• Acute nonlymphoblastic leukemia
• Prostate cancer
• Breast cancer
• Non-Hodgkin's lymphoma
How the Drug Works
• A
DNA-reactive agent that causes crosslinks and strand breaks, interferes
with DNA uncoiling and repair, and has a cytocidal
effect on cells. In MS, it appears
to blunt the immune processes believed to be responsible in part for the
disease
• It
suppresses B-cell, T-cell, and macrophage function, impairs antigen
proliferation, and decreases the secretion of inflammatory
cytokines, including TNFα, IL-2, and
interferon gamma, that mediate demyelination
• Due to its slow release from sequestered tissue into blood it is a long-acting immunosuppressant
How Long Until It Works
• MS: Months-years. In trials treated patients had fewer relapses at 1 and 2 years
If It Works
• MS: Continue to use for up to 2-3 years or a total of 140 mg/m2 then discontinue because of cardiotoxicity risk
If It Doesn't Work
• For
patients failing first-line agents in MS (interferons, glatiramer) and
mitoxantrone with frequent relapses (measured by
clinical outcome and MRI
accumulation of lesions) consider using natalizumab, monthly
methylprednisolone, or pulse cyclophosphamide
Best Augmenting Combos for Partial Response or Treatment-Resistance
• Acute attacks in MS are often treated with glucocorticoids, especially if there is functional impairment due to vision loss,
weakness, or cerebellar symptoms
• Treat common clinical symptoms with appropriate medication for spasticity (baclofen, tizanidine), neuropathic pain, and fatigue
(modafinil)
• Generally
not combined with most other MS disease-modifying treatments
(natalizumab, interferons, glatiramer) but 1 study
showed that adding monthly
mitoxantrone to monthly doses of 1 gram methylprednisolone improved
outcomes
Tests
• Assess
cardiac left ventricular function using echocardiogram or MUGA (multi
gated acquisition scan) at baseline and before
each dose of mitoxantrone. Obtain a
baseline blood count and recheck if symptoms of infection occur